Advances in therapy for pediatric sarcomas

Aaron Weiss, Jonathan Gill, John Goldberg, Joanne Lagmay, Holly Spraker-Perlman, Rajkumar Venkatramani, Damon Reed

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Pediatric sarcomas are relatively rare malignancies individually. As a group they are typically approached with combination chemotherapies in addition to local control. Fortunately, these malignancies have been approached through careful clinical trial collaboration to define risk groups and appropriately deliver local control measures and systemic therapies. Although local disease is typically approached with curative intent, therapy typically lasts over 6 months and has significant associated morbidities. It is more difficult to cure metastatic disease or induce sustained remissions. In this article, we discuss recent advances in the understanding of the disease process and highlight recent and future cooperative group trials in osteosarcoma, Ewing sarcoma, rhabdomyosarcoma, nonrhabdomyosarcoma soft tissue sarcomas, and desmoid tumor as well as discuss promising therapeutic approaches such as epigenetics and immunotherapy.

Original languageEnglish
Article number395
JournalCurrent Oncology Reports
Volume16
Issue number8
DOIs
StatePublished - Jan 1 2014
Externally publishedYes

Fingerprint

Sarcoma
Pediatrics
Aggressive Fibromatosis
Neoplasms
Ewing's Sarcoma
Rhabdomyosarcoma
Osteosarcoma
Combination Drug Therapy
Epigenomics
Immunotherapy
Therapeutics
Clinical Trials
Morbidity

Keywords

  • Oncology
  • Pediatric sarcomas
  • Rare malignancies
  • Sarcomas
  • Therapy

ASJC Scopus subject areas

  • Oncology

Cite this

Weiss, A., Gill, J., Goldberg, J., Lagmay, J., Spraker-Perlman, H., Venkatramani, R., & Reed, D. (2014). Advances in therapy for pediatric sarcomas. Current Oncology Reports, 16(8), [395]. https://doi.org/10.1007/s11912-014-0395-z

Advances in therapy for pediatric sarcomas. / Weiss, Aaron; Gill, Jonathan; Goldberg, John; Lagmay, Joanne; Spraker-Perlman, Holly; Venkatramani, Rajkumar; Reed, Damon.

In: Current Oncology Reports, Vol. 16, No. 8, 395, 01.01.2014.

Research output: Contribution to journalArticle

Weiss, A, Gill, J, Goldberg, J, Lagmay, J, Spraker-Perlman, H, Venkatramani, R & Reed, D 2014, 'Advances in therapy for pediatric sarcomas', Current Oncology Reports, vol. 16, no. 8, 395. https://doi.org/10.1007/s11912-014-0395-z
Weiss A, Gill J, Goldberg J, Lagmay J, Spraker-Perlman H, Venkatramani R et al. Advances in therapy for pediatric sarcomas. Current Oncology Reports. 2014 Jan 1;16(8). 395. https://doi.org/10.1007/s11912-014-0395-z
Weiss, Aaron ; Gill, Jonathan ; Goldberg, John ; Lagmay, Joanne ; Spraker-Perlman, Holly ; Venkatramani, Rajkumar ; Reed, Damon. / Advances in therapy for pediatric sarcomas. In: Current Oncology Reports. 2014 ; Vol. 16, No. 8.
@article{b41719824a884b57aa0d5b43e3c0b78d,
title = "Advances in therapy for pediatric sarcomas",
abstract = "Pediatric sarcomas are relatively rare malignancies individually. As a group they are typically approached with combination chemotherapies in addition to local control. Fortunately, these malignancies have been approached through careful clinical trial collaboration to define risk groups and appropriately deliver local control measures and systemic therapies. Although local disease is typically approached with curative intent, therapy typically lasts over 6 months and has significant associated morbidities. It is more difficult to cure metastatic disease or induce sustained remissions. In this article, we discuss recent advances in the understanding of the disease process and highlight recent and future cooperative group trials in osteosarcoma, Ewing sarcoma, rhabdomyosarcoma, nonrhabdomyosarcoma soft tissue sarcomas, and desmoid tumor as well as discuss promising therapeutic approaches such as epigenetics and immunotherapy.",
keywords = "Oncology, Pediatric sarcomas, Rare malignancies, Sarcomas, Therapy",
author = "Aaron Weiss and Jonathan Gill and John Goldberg and Joanne Lagmay and Holly Spraker-Perlman and Rajkumar Venkatramani and Damon Reed",
year = "2014",
month = "1",
day = "1",
doi = "10.1007/s11912-014-0395-z",
language = "English",
volume = "16",
journal = "Current Oncology Reports",
issn = "1523-3790",
publisher = "Current Science, Inc.",
number = "8",

}

TY - JOUR

T1 - Advances in therapy for pediatric sarcomas

AU - Weiss, Aaron

AU - Gill, Jonathan

AU - Goldberg, John

AU - Lagmay, Joanne

AU - Spraker-Perlman, Holly

AU - Venkatramani, Rajkumar

AU - Reed, Damon

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Pediatric sarcomas are relatively rare malignancies individually. As a group they are typically approached with combination chemotherapies in addition to local control. Fortunately, these malignancies have been approached through careful clinical trial collaboration to define risk groups and appropriately deliver local control measures and systemic therapies. Although local disease is typically approached with curative intent, therapy typically lasts over 6 months and has significant associated morbidities. It is more difficult to cure metastatic disease or induce sustained remissions. In this article, we discuss recent advances in the understanding of the disease process and highlight recent and future cooperative group trials in osteosarcoma, Ewing sarcoma, rhabdomyosarcoma, nonrhabdomyosarcoma soft tissue sarcomas, and desmoid tumor as well as discuss promising therapeutic approaches such as epigenetics and immunotherapy.

AB - Pediatric sarcomas are relatively rare malignancies individually. As a group they are typically approached with combination chemotherapies in addition to local control. Fortunately, these malignancies have been approached through careful clinical trial collaboration to define risk groups and appropriately deliver local control measures and systemic therapies. Although local disease is typically approached with curative intent, therapy typically lasts over 6 months and has significant associated morbidities. It is more difficult to cure metastatic disease or induce sustained remissions. In this article, we discuss recent advances in the understanding of the disease process and highlight recent and future cooperative group trials in osteosarcoma, Ewing sarcoma, rhabdomyosarcoma, nonrhabdomyosarcoma soft tissue sarcomas, and desmoid tumor as well as discuss promising therapeutic approaches such as epigenetics and immunotherapy.

KW - Oncology

KW - Pediatric sarcomas

KW - Rare malignancies

KW - Sarcomas

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=84901732194&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901732194&partnerID=8YFLogxK

U2 - 10.1007/s11912-014-0395-z

DO - 10.1007/s11912-014-0395-z

M3 - Article

VL - 16

JO - Current Oncology Reports

JF - Current Oncology Reports

SN - 1523-3790

IS - 8

M1 - 395

ER -